<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Brolucizumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Brolucizumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Brolucizumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="122891" href="/d/html/122891.html" rel="external">see "Brolucizumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53741544"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Beovu</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54460008"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Beovu</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53733598"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Ophthalmic Agent;</li>
<li>
                        Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F53778640"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="00dc0d3a-8e07-431d-8cf1-8d2a58a1c1bc">Age-related macular degeneration, neovascular</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Age-related macular degeneration, neovascular (wet):</b>
<b>Intravitreal:</b> 6 mg once per month (approximately every 25 to 31 days) for 3 months, followed by 6 mg once every 8 to 12 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="867af98d-205e-460e-8955-a72b16570934">Diabetic macular edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic macular edema: Intravitreal: </b>6 mg every 6 weeks (approximately every 39 to 45 days) for 5 doses, followed by 6 mg once every 8 to 12 weeks.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F53778642"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F53778643"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F53778641"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F53736528"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Immunologic: Antibody development (53% to 67%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thromboembolism (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal sensation in eyes (≤1%), blindness (1%), blurred vision (2% to10%), cataract (4% to 7%), conjunctival hemorrhage (6%), conjunctival hyperemia (≤1%), conjunctivitis (2% to 3%), corneal abrasion (1% to 2%), endophthalmitis (≤1%), eye pain (3% to 5%), increased intraocular pressure (2% to 4%), increased lacrimation (≤1%), intraocular inflammation (3% to 6%), punctate keratitis (1%), retinal artery occlusion (1%), retinal detachment (1%), retinal hemorrhage (4%), retinal hole without detachment (≤1%), retinal pigment epithelium detachment (1%), retinal pigment epithelium tear (3%), vitreous detachment (2% to 4%), vitreous hemorrhage (≤1%), vitreous opacity (3% to 5%)</p>
<p style="text-indent:-4em;margin-left:4em;">Postmarketing: Ophthalmic: Retinopathy (retinal vasculitis and retinal vein occlusion)</p></div>
<div class="block coi drugH1Div" id="F53733601"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, rash, pruritus, urticaria, erythema, severe intraocular inflammation) to brolucizumab or any component of the formulation; ocular or periocular infections; active intraocular inflammation.</p></div>
<div class="block war drugH1Div" id="F53778627"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Endophthalmitis and retinal detachment: Intravitreal injections may be associated with endophthalmitis and retinal detachment. Use proper aseptic injection technique. Monitor for and report symptoms (eg, eye pain, redness of the eye, photophobia, blurred vision) immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intraocular pressure: Acute (within 30 minutes) and sustained increases in increased intraocular pressure (IOP) have occurred. Monitor IOP (via tonometry) and optic nerve head perfusion immediately following administration and manage appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal vasculitis/retinal vascular occlusion: Cases of retinal vasculitis and/or retinal vascular occlusion have been reported, usually associated with intraocular inflammation, and are attributed to an immune-mediated adverse event; may occur with the first intravitreal injection. Discontinue therapy if signs and symptoms occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: Risk of arterial thromboembolic events (eg, nonfatal stroke, nonfatal myocardial infarction, vascular death) may be increased with intravitreal use of vascular endothelial growth factor inhibitors.</p></div>
<div class="block foc drugH1Div" id="F53741545"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravitreal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Beovu: Brolucizumab-dbll 6 mg/0.05 mL (0.05 mL [DSC]) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravitreal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Beovu: Brolucizumab-dbll 6 mg/0.05 mL (0.05 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F53741543"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53793960"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Beovu Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg/0.05 mL (per 0.05 mL): $2,355.88</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54460009"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravitreal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Beovu: Brolucizumab-dbll 6 mg/0.05 mL (0.05 mL) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F53778644"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;">
<b>Intravitreal:</b> For ophthalmic intravitreal injection only. Each prefilled syringe or vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new prefilled syringe or vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before brolucizumab is administered to the other eye. Adequate anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure. Refer to manufacturer's labeling for additional detailed information.</p></div>
<div class="block use drugH1Div" id="F53733600"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Age-related macular degeneration, wet (neovascular):</b> Treatment of neovascular (wet) age-related macular degeneration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic macular edema:</b> Treatment of diabetic macular edema.</p></div>
<div class="block mst drugH1Div" id="F53778623"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Brolucizumab may be confused with bevacizumab</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F53754786"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53754783"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53778625"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use highly effective contraception (methods with pregnancy rates &lt;1%) during therapy and for ≥1 month following the last brolucizumab dose.</p></div>
<div class="block pri drugH1Div" id="F53778624"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor; VEGF is required to achieve and maintain normal pregnancies (Peracha 2016). Based on the mechanism of action, brolucizumab may cause fetal harm if administered to a pregnant patient.</p></div>
<div class="block brc drugH1Div" id="F53778626"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if brolucizumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for ≥1 month following the last brolucizumab dose.</p></div>
<div class="block mop drugH1Div" id="F53778646"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Intraocular pressure (via tonometry) and optic nerve head perfusion immediately following administration; symptoms of endophthalmitis and retinal detachment; symptoms of retinal vasculitis and retinal vascular occlusion (especially in patients with intraocular inflammation), vision changes.</p></div>
<div class="block pha drugH1Div" id="F53778635"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Brolucizumab is a recombinant humanized monoclonal antibody vascular endothelial growth factor (VEGF) inhibitor that binds to the 3 major isoforms of VEGF-A, thereby suppressing endothelial cell proliferation, neovascularization, and vascular permeability to slow vision loss.</p></div>
<div class="block phk drugH1Div" id="F53778636"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not fully characterized; free brolucizumab is expected to undergo proteolysis.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 4.4 ± 2 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Serum: 24 hours (free brolucizumab).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58846810"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Beovu</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Beovu (brolucizumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2023.</div>
</li>
<li>
<div class="reference">
                  Beovu (brolucizumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27388726">
<a name="27388726"></a>Peracha ZH, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy in pregnancy: what we know, what we don't know, and what we don't know we don't know. <i>Retina</i>. 2016;36(8):1413-1417. doi: 10.1097/IAE.0000000000001200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brolucizumab-drug-information/abstract-text/27388726/pubmed" id="27388726" target="_blank">27388726</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 122820 Version 65.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
